Why You Don't Need to Cycle CJC-1295 or Tesamorelin
The cycling advice that gets passed around for peptide protocols usually treats CJC-1295 and Ipamorelin as a single unit, because they are sold that way, mixed in the same vial, used at the same time, and assumed to follow the same rules. But they operate through two completely separate receptor systems inside your pituitary gland, and those two systems do not behave the same way when you stimulate them continuously. Understanding that difference is what lets you build a protocol based on how the biology actually works rather than on a rule that got copied from one forum to the next.
Your pituitary gland releases growth hormone in response to two distinct upstream signals. The first comes from something called growth hormone releasing hormone, or GHRH, which is a peptide your hypothalamus produces to tell the pituitary it is time to release growth hormone. The second comes from something called ghrelin, which is a hunger-signaling peptide that works through an entirely different receptor family and has its own separate pathway into the same output. Both signals increase growth hormone, but they do it through different locks on the same door, and only one of those locks has a problem with being left in the on position for too long.
That problem lock is the ghrelin receptor system, and it is where Ipamorelin works.
When you stimulate ghrelin receptors repeatedly, your body begins pulling those receptors off the surface of the cell through a process called beta-arrestin mediated internalization, which is essentially the cell physically removing its own receptor from the membrane so it cannot keep receiving the signal. The more frequently you stimulate these receptors without giving them adequate recovery, the fewer of them remain on the cell surface, and the weaker your growth hormone response becomes over time. A 16-week human trial tracking this exact mechanism found that continuous ghrelin receptor stimulation caused the growth hormone response to decline by roughly 45 percent from baseline by week 16. When subjects stopped for four weeks, the response came all the way back. The receptors had time to be recycled back to the surface, and the system recovered completely.
That is the real biological reason you cycle Ipamorelin. Three months on, one month off is not arbitrary. It maps to the timeline of receptor downregulation and the recovery window needed to restore sensitivity.
Now here is where CJC-1295 and tesamorelin fit into this, and why they are a different conversation entirely.
Both of these compounds are analogs of GHRH, meaning they work on the growth hormone releasing hormone receptor, not the ghrelin receptor. Lab work using perifused rat pituitary cells showed that these two receptor systems are fully independent, meaning you can desensitize one without affecting the other, and stimulating one does not accelerate desensitization in the other. They are parallel pathways that feed into the same output but do not share the same regulatory machinery.
This independence matters because it means the cycling logic built around ghrelin receptor downregulation does not automatically transfer to GHRH receptor behavior.
Tesamorelin is the clearest example of how this plays out in human data. It was tested in Phase 3 clinical trials with patients receiving daily injections for 52 consecutive weeks, and IGF-1 levels, which reflect sustained growth hormone activity in the body, held steady through the entire period with no statistically significant decline. That is a full year of daily dosing without the receptor desensitization pattern that ghrelin-pathway peptides produce. The FDA approved tesamorelin based partly on this sustained-effect profile, and the prescribing data from that approval reflects the same conclusion.
The reason GHRH-based peptides avoid this problem comes down to pharmacokinetics, which is just a term for how long a drug stays active in your body after you take it. Tesamorelin has a half-life of approximately 26 to 38 minutes. When you inject it, it delivers a brief pulse of GHRH-receptor stimulation and then clears the system. Your GHRH receptors get a real signal, respond, and then have more than 23 hours with essentially no signal present before the next injection. That is a recovery window, built into the dosing schedule by the drug's own short duration of action, and it appears to be sufficient to prevent the internalization problem that continuous stimulation would otherwise cause.
Ghrelin receptor systems do not get that same protection under typical Ipamorelin protocols, because the receptor binding dynamics and signaling patterns differ enough that the same recovery window does not prevent downregulation the same way.
Some evidence from ghrelin mimetics supports this further. MK-677, which is an oral ghrelin mimetic that activates the same receptor pathway as Ipamorelin, was studied over two years of continuous daily use and maintained IGF-1 elevation throughout, which seems to contradict the desensitization data. The difference is likely in dosing frequency and receptor occupancy over time, and it suggests the system is more nuanced than a simple on-off switch, but it does not change the practical picture for injectable Ipamorelin protocols given how those are typically administered.
What this means practically is straightforward. If you are running CJC-1295 or Ipamorelin from a combination vial, you cycle it because of the Ipamorelin component. The CJC is going along for the ride on that cycle schedule, not because it needs one. If you are running tesamorelin on its own, there is no published human evidence suggesting you need to cycle it. The 52-week data says the receptor does not behave that way under daily pulsatile administration.
Most cycling rules in peptide use exist because someone took a real mechanism that applies to one compound and applied it universally to everything in the same category. Ipamorelin and tesamorelin both raise growth hormone, so the assumption was that the rules for one apply to the other. But receptor biology does not work by category. It works by mechanism. And when the mechanisms are different, the rules are different.
That is the whole point.
References
- Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res. 1998;8 Suppl B:141-143 — 16-week human trial showing 45% GH response decline with continuous ghrelin receptor stimulation, full recovery after 4 weeks off. Source
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. NEJM. 2007 — Tesamorelin daily dosing for 26 weeks with sustained IGF-1 elevation. Source
- FDA Prescribing Information. EGRIFTA (tesamorelin). 2010/2025 — 52-week pooled Phase 3 data showing sustained IGF-1 and VAT reduction through week 52
- Blake AD, Smith RG. Desensitization studies using perifused rat pituitary cells. J Endocrinol. 1991;1291:11-19 — Proved GHRH and ghrelin receptor systems are independent with no cross-desensitization. Source
- Nass R et al. Effects of an oral ghrelin mimetic on body composition in healthy older adults. Ann Intern Med. 2008;1499:601-611 — MK-677 ghrelin mimetic maintained GH/IGF-1 elevation for 2 years of continuous use. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.